BioSpace News Archive

Nexus Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Busulfan Injection, the company’s AP-rated therapeutic equivalent for Busulfex® 60 mg/10 mL (6 mg/1 mL).

CANNAMERICA BRANDS CORP. (“CANA” or the “Company”) (CSE: CANA) (OTCQB: CNNXF) is pleased to provide an update on its binding letter of intent (“LOI”) to create a joint venture with Invictus MD Stategies Corp. (“Invictus”) (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) and CBDistribution Company Ltd. (“CBDC”) (collectively the “Joint Venture”) that was previously announced on January 7, 2019

An inventor from Temecula, Calif., has developed RANDY’S TRACHEAL SUCTION MACHINE, a new type of respiratory therapy device.

Nominations now open for 2019 American Humane Hero Veterinarian and Hero Veterinary Nurse Awards™, sponsored by Zoetis Petcare; Winners to be featured in national television broadcast

Introduction of Orbital Atherectomy in the Middle East by OrbusNeich® Expands Treatment Options for Patients with Complex Coronary Artery Disease

Protagonist Therapeutics, Inc. reported that on Jan. 15, 2019, it issued an inducement award to Suneel Gupta, Ph.D., the Company’s recently hired Executive Vice President of Clinical Operations and Pharmacology, in accordance with the terms of Dr. Gupta’s employment offer letter.

Aurora Cannabis Inc. announced that it proposes to offer pursuant to a private placement US$250.0 million aggregate principal amount of convertible senior notes due 2024 (the “notes”)

Middlefield Healthcare & Life Sciences Dividend Fund is pleased to announce that distributions for the first quarter of 2019 will be payable to unitholders of Middlefield Healthcare & Life Sciences Dividend Fund

The world’s first non-invasive home-cell collection service will allow consumers to easily collect live cells for future therapeutic uses.

Innovent Biologics, Inc. announced that the first patient has been dosed in a phase III clinical trial (ORIENT-16) that is to evaluate Tyvyt®, in combination with capecitabine and oxaliplatin, as first-line treatment for patients with advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma (GC or GEJ).